Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma

Journal of Clinical Oncology

Volumn 25, Issue 11, 2007, Pages 1369-1376

  Ganly, Ian ^a   Talbot, Simon ^a   Carlson, Diane ^a   Viale, Agnes ^a   Maghami, Ellie ^a   Osman, Iman ^a   Sherman, Eric ^a   Pfister, David ^a   Chuai, Shaokun ^a   Shaha, Ashok R ^a   Kraus, Dennis ^a   Shah, Jatin P ^a   Socci, Nicholas D ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; RAS PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FROZEN SECTION; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

DISEASE-FREE SURVIVAL; DNA PRIMERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; MICROARRAY ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARYNGEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC;

EID: 34248169630     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.3397     Document Type: Article

References (54)

1. Wolf G, Hong K, Fisher S, et al: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
2. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 34:890-899, 1996
3. Giralt JL, Gonzalez J, del Campo, JM, et al: Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 89:939-945, 2000
4. Harrison LB, Pfister DG, Fass DE, et al: Concomitant chemotherapy- radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. Int J Radiat Oncol Biol Phys 21:703-708, 1991
5. Pfister DG, Harrison LB, Strong EW, et al: Organ function preservation in advanced oropharynx cancer: Results with induction chemotherapy and radiation. J Clin Oncol 13:671-680, 1995
6. Ganly I, Patel SG, Matsuo J, et al: Postoperative complications of salvage total laryngectomy. Cancer 103:2073-2081, 2005
7. Bradford CR, Zhu S, Wolf GT, et al: Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer: Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 113:408-412, 1995
8. Lavertu P, Adelstein DJ, Myles J, et al: p53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. Laryngoscope 111:1878-1891, 2001
9. Osman I, Sherman E, Singh B, et al: Alteration of p53 pathway in squamous cell carcinoma of the head and neck: Impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 20:2980-2987, 2002
10. Trask DK, Wolf GT, Bradford CR, et al: Expression of Bcl- family proteins in advanced laryngeal squamous cell carcinoma: Correlation with response to chemotherapy and organ preservation. Laryngoscope 112:638-644, 2002
11. Kihari C, Tsunoda T, Tanaka T, et al: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene expression profiles. Cancer Res 61:6474-6479, 2001
12. Okutsu J, Tsunoda T, Kaneta Y, et al: Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 1:1035-1042, 2002
13. Mariadason JM, Arango D, Shi Q, et al: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 15:8791-8812, 2003
14. Kikuchi T, Daigo Y, Katagiri T, et al: Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anticancer drugs. Oncogene 22:2192-2205, 2003
15. Ochi K, Daigo Y, Katagiri T, et al: Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene expression profiles. Int J Oncol 24:647-655, 2004
16. Giatromanolaki A, Koukourakis MI, Georgoulias V, et al: Angiogenesis vs. response after combined chemo-radiotherapy of squamous cell head and neck cancer. Int J Cancer 80:810-817, 1999
17. Koukourakis MI, Giatromanolaki A, Fountzilas G, et al: Angiogenesis, thymidine phosphorylase and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 6:381-389, 2000
18. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head and neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
19. Belbin TJ, Singh B, Barber I, et al: Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62: 1184-1190, 2002
20. Yang YH, Dudoit S, Luu P, et al: Normalization for cDNA microarray data: A robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15, 2002
21. Schadt EE, Li C, Ellis B, et al: Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 37:120-125, 2001
22. Tseng GC, Oh MK, Rohlin L, et al: Issues in cDNA microarray analysis: Quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 29:2549-2557, 2001
23. Davison AC, Hinkley DV: Bootstrap Methods and Their Application. Cambridge, United Kingdom, Cambridge University Press, 1997
24. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. London, United Kingdom, Chapman & Hall, 1994
25. Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping gene expression: Validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 46:69-81, 2000
26. Morrison TB, Weis JJ, Wittwer CT: Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954-958, 1998
27. Eisbruch A, Thornton AF, Urba S, et al: Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. J Clin Oncol 14:2322-2330, 1996
28. Weber RS, Berkey BA, Forastiere A, et al: Outcome of salvage total laryngectomy following organ preservation therapy. Arch Otolaryngol Head Neck Surg 129:44-49, 2003
29. Bradford CR, Zhu S, Ogawa H, et al: p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25:654-661, 2003
30. Casado S, Forteza J, Dominguez S, et al: Predictive value of p53, Bcl-2 and bax in advanced head and neck carcinoma. Am J Clin Oncol 25:588-590, 2002
31. Gasparini G, Bevilacqua P, Bonoldi E, et al: Predictive and prognostic markers in a series of patients with head and neck SCC treated with concurrent chemoradiotherapy. Clin Cancer Res 1:1375-1383, 1995
32. DeRisi J, Penland L, Brown PO, et al: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457-460, 1996
33. Scherf U, Ross DT, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236-244, 2000
34. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1595, 1991
35. Jones SN, Hancock AR, Vogel H, et al: Overexpression of MDM2 in mice reveals a p53 independent role for MDM2 in tumorigenesis. Proc Natl Acad Sci U S A 95:15608-15612, 1998
36. Ikeguchi M, Ueda T, Fukuda K, et al: Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am J Clin Oncol 25:454-459, 2002
37. Sato N, Mizumoto K, Machara N, et al: Enhancement of drug-induced apoptosis by antisense oligonucleotides targeted against MDM2 and P21WAF1/CIP1. Anticancer Res 20:837-842, 2000
38. Wang H, Zeng X, Oliver P, et al: MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol 15:653-660, 1999
39. Bianco R, Ciardiello F, Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets 5:51-56, 2005
40. Wang H, Oliver P, Zhang Z, et al: Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217-235, 2003
41. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986
42. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
43. Signoretti S, Montironi R, Manola J, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Institute 92:1918-1925, 2000
44. Xia W, Lau YK, Zhang HZ, et al: Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 3:3-9, 1997
45. Khan AJ, King BL, Smith BD, et al: Characterisation of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8:540-548, 2002
46. Beckhardt RN, Kiyokawa N, Xi L, et al: HER-2-neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 121:1265-1270, 1995
47. Riviere A, Wilckens C, Loning T: Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinoma of the head and neck and the lower female genital tract. J Oral Pathol Med 19: 408-413, 1990
48. Field JK, Spandidos DA, Yiagnisis M: c-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 12:613-620, 1992
49. Craven JM, Pavelic ZP, Stambrook PJ, et al: Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 12:2273-2276, 1992
50. Ibrahim SO, Vasstrand EN, Liavaag PG, et al: Expression of c-erbB-2 proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 17:4539-4546, 1997
51. Silva SD, Agostini M, Nishimoto IN, et al: Expression of fatty acid synthase, erbB2 and KI-67 in head and neck squamous cell carcinoma: A clinico-pathological study. Oral Oncol 40:688-696, 2004
52. Akamatsu M, Matsumoto T, Oka K, et al: C-erbB-2 oncoprotein expression related to chemo-radioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57:1323-1327, 2003
53. Nishioka T, West CML, Gupta N, et al: Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy. J Cancer Res Clin Oncol 125:96-100, 1999
54. Uno M, Otsuki T, Kurebayashi J, et al: Anti-HER2 antibody enhances radiation induced growth inhibition in head and neck carcinoma. Int J Cancer 94:474-479, 2001